Cavadis Overview

  • Founded
  • 2007
  • Status
  • Out of Business
  • Latest Deal Type
  • Liquidation

Cavadis General Information


Developer of prognostic tests designed to identify patients at risk of cardiovascular diseases. The company's tests identify the risk of developing heart attacks and strokes as well as offer biomarkers that outperform traditional risk factors and show an impressive shifting power in patients classified as a high or low risk, enabling physicians to personalize treatment and achieve better patient outcomes.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Therapeutic Devices
Primary Office
  • Koninginneweg 16
  • 1217 KZ Hilversum
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cavadis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Bankruptcy: Liquidation 00.000 Completed Bankruptcy: Liquidation
4. Grant 12-Feb-2010 00000 00.000 Completed Startup
3. Debt - General 09-Nov-2009 00.000 00.000 Completed Startup
2. Early Stage VC (Series A) 26-May-2009 Completed Startup
1. Seed Round 25-Oct-2007 Completed Startup
To view Cavadis’s complete valuation and funding history, request access »

Cavadis Executive Team (3)

Name Title Board Seat Contact Info
Dominique de Kleijn Ph.D Chief Technology Officer
Gerard Pasterkamp Ph.D Chief Scientific Officer
Heico Breek MD Chief Executive Officer
To view Cavadis’s complete executive team members history, request access »